reports
TG Therapeutics Provides Business Update and Reports First Quarter 202...
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan...
TG Therapeutics to Host Conference Call on First Quarter 2024 Financia...
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-40...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. ...
TG Therapeutics Awarded National Contract by the Department of Veteran...
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of ...
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituxim...
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional pre...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now av...
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multipl...
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach,...
TG Therapeutics Provides Business Update and Reports Fourth Quarter an...
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.Michael S. Weiss, the Company's Chairman and Chief E...
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® ...
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy) Newly issued patents extend exclusivity of ublituximab through 2042 NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting do...
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xii...
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy) Ex-US partner, Neuraxpharm, launches BRIUMVI in Germany, the first European country NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG Therapeutics) today announced that its ex-US partner, Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, launched BRIUMVI® (ublituximab-xiiy) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis (RMS), who have ...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, February 28, 2024, at 8:30 AM ET to discuss results for the fourth quarter and year-end 2023 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference cal...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Scle...
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023...
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively Preliminary year-end 2023 cash position of approximately $215 million NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023 (unaudite...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TAST CARROLS RESTAURANT GROUP INC
SWN SOUTHWESTERN ENERGY COMPANY
FHN FIRST HORIZON CORPORATION
D8Q BANCO LATINOAMERICANO DE COMERCIO EXTERIOR S.A. CLASS E
AXGN AXOGEN INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
APEI AMERICAN PUBLIC EDUCATION
SYF SYNCHRONY FINANCIAL
TATT TAT TECHNOLOGIES LTD.
LNC LINCOLN NATIONAL CORPORATION
NRP NATURAL RESOURCE PARTNERS L.P.
MLP MAUI LAND & PINEAPPLE CO. INC.
HBB HAMILTON BEACH BRANDS HOLDING COMPANY
AGS PLAYAGS INC
SSNT SILVERSUN TECHNOLOGIES
ELAN ELANCO ANIMAL HEALTH INC.
YMAB Y-MABS THERAPEUTICS
INMB INMUNE BIO
LEVI LEVI STRAUSS & CO. CLASS A
HOV HOVNANIAN ENTERPRISES INC. CLASS A
IGMS IGM BIOSCIENCES
PNTG PENNANT GROUP
KRUS KURA SUSHI USA
ETRN EQUITRANS MIDSTREAM CORP.
STTK SHATTUCK LABS
IMVT IMMUNOVANT
VTRS VIATRIS INC.
CBRG CHAIN BRIDGE I
LUXH LUXURBAN HOTELS INC
NGNE NEUROGENE INC
TG Therapeutics Announces Global License Agreement with Precision BioS...
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases US IND filing targeted for mid-2024 NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today with , Inc. ( GS: DTIL) to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications. Azer-cel is an a...
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthca...
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PT NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Tuesday, January 9, 2024, at 4:30 PM PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media se...
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCO...
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 6th Annual Evercore ISI HealthCONx Conference, being held at the Kimpton EPIC Hotel, in Miami, Florida on November 28 - 30, 2023. The fireside chat is scheduled to take place on Wednesday, November 29, 2023, at 2:10 PM ET. A live webcast ...
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammati...
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference Fireside chat scheduled for Monday, November 6, 2023, at 3:10 PM ET NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023. The fireside chat is scheduled to take place on Monday...
TG Therapeutics Provides Business Update and Reports Third Quarter 202...
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm Approximately 2,200 BRIUMVI prescriptions since launch from 500+ healthcare providers at approximately 350 centers across the U.S. Payor coverage in place for approximately 95% of covered lives for BRIUMVI Conference call to be held today, November 1, 2023, at 8:30 AM ET NEW Y...
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financia...
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will host the call. In order to participate in the conference...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.